These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 24338699)

  • 21. Direct and Indirect Healthcare Resource Utilization and Costs Among Migraine Patients in the United States.
    Bonafede M; Sapra S; Shah N; Tepper S; Cappell K; Desai P
    Headache; 2018 May; 58(5):700-714. PubMed ID: 29446063
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Controlled Trial of Erenumab for Episodic Migraine.
    Goadsby PJ; Reuter U; Hallström Y; Broessner G; Bonner JH; Zhang F; Sapra S; Picard H; Mikol DD; Lenz RA
    N Engl J Med; 2017 Nov; 377(22):2123-2132. PubMed ID: 29171821
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Integrated care for chronic migraine patients: epidemiology, burden, diagnosis and treatment options.
    Diener HC; Solbach K; Holle D; Gaul C
    Clin Med (Lond); 2015 Aug; 15(4):344-50. PubMed ID: 26407383
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Erenumab (AMG 334) in episodic migraine: Interim analysis of an ongoing open-label study.
    Ashina M; Dodick D; Goadsby PJ; Reuter U; Silberstein S; Zhang F; Gage JR; Cheng S; Mikol DD; Lenz RA
    Neurology; 2017 Sep; 89(12):1237-1243. PubMed ID: 28835404
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The prevalence, burden, and treatment of severe, frequent, and migraine headaches in US minority populations: statistics from National Survey studies.
    Loder S; Sheikh HU; Loder E
    Headache; 2015 Feb; 55(2):214-28. PubMed ID: 25644596
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Migraine affects 1 in 10 people worldwide featuring recent rise: A systematic review and meta-analysis of community-based studies involving 6 million participants.
    Woldeamanuel YW; Cowan RP
    J Neurol Sci; 2017 Jan; 372():307-315. PubMed ID: 28017235
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chronic migraine: risk factors, mechanisms and treatment.
    May A; Schulte LH
    Nat Rev Neurol; 2016 Aug; 12(8):455-64. PubMed ID: 27389092
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Estimating the clinical effectiveness and value-based price range of erenumab for the prevention of migraine in patients with prior treatment failures: a US societal perspective.
    Lipton RB; Brennan A; Palmer S; Hatswell AJ; Porter JK; Sapra S; Villa G; Shah N; Tepper S; Dodick D
    J Med Econ; 2018 Jul; 21(7):666-675. PubMed ID: 29571276
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chronic migraine.
    Schwedt TJ
    BMJ; 2014 Mar; 348():g1416. PubMed ID: 24662044
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Real-World Analysis of Migraine: A Cross-Sectional Study of Disease Burden and Treatment Patterns.
    Ford JH; Jackson J; Milligan G; Cotton S; Ahl J; Aurora SK
    Headache; 2017 Nov; 57(10):1532-1544. PubMed ID: 28984356
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The impact of headache in Europe: principal results of the Eurolight project.
    Steiner TJ; Stovner LJ; Katsarava Z; Lainez JM; Lampl C; Lantéri-Minet M; Rastenyte D; Ruiz de la Torre E; Tassorelli C; Barré J; Andrée C
    J Headache Pain; 2014 May; 15(1):31. PubMed ID: 24884549
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The acute treatment of migraine in adults: the american headache society evidence assessment of migraine pharmacotherapies.
    Marmura MJ; Silberstein SD; Schwedt TJ
    Headache; 2015 Jan; 55(1):3-20. PubMed ID: 25600718
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Burden of migraine: what should we say more?
    Leonardi M
    Neurol Sci; 2015 May; 36 Suppl 1():1-3. PubMed ID: 26017501
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Prevalence and Impact of Migraine and Severe Headache in the United States: Figures and Trends From Government Health Studies.
    Burch R; Rizzoli P; Loder E
    Headache; 2018 Apr; 58(4):496-505. PubMed ID: 29527677
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of Galcanezumab for the Prevention of Episodic Migraine: The EVOLVE-1 Randomized Clinical Trial.
    Stauffer VL; Dodick DW; Zhang Q; Carter JN; Ailani J; Conley RR
    JAMA Neurol; 2018 Sep; 75(9):1080-1088. PubMed ID: 29813147
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adherence to oral migraine-preventive medications among patients with chronic migraine.
    Hepp Z; Dodick DW; Varon SF; Gillard P; Hansen RN; Devine EB
    Cephalalgia; 2015 May; 35(6):478-88. PubMed ID: 25164920
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial.
    Sun H; Dodick DW; Silberstein S; Goadsby PJ; Reuter U; Ashina M; Saper J; Cady R; Chon Y; Dietrich J; Lenz R
    Lancet Neurol; 2016 Apr; 15(4):382-90. PubMed ID: 26879279
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fluctuations in episodic and chronic migraine status over the course of 1 year: implications for diagnosis, treatment and clinical trial design.
    Serrano D; Lipton RB; Scher AI; Reed ML; Stewart WBF; Adams AM; Buse DC
    J Headache Pain; 2017 Oct; 18(1):101. PubMed ID: 28980171
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fremanezumab as Add-On Treatment for Patients Treated With Other Migraine Preventive Medicines.
    Cohen JM; Dodick DW; Yang R; Newman LC; Li T; Aycardi E; Bigal ME
    Headache; 2017 Oct; 57(9):1375-1384. PubMed ID: 28862758
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sex differences in the epidemiology, clinical features, and pathophysiology of migraine.
    Vetvik KG; MacGregor EA
    Lancet Neurol; 2017 Jan; 16(1):76-87. PubMed ID: 27836433
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.